Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Gabriel RinnerthalerSimon Peter GampenriederHubert HacklMarkus SteinerClaudia Monzo-FuentesThomas MelchardtTeresa MagnesFlorian HuemerTheresa WestphalClemens HufnaglCornelia Hauser-KronbergerAlexander EgleRichard GreilPublished in: Journal of clinical medicine (2020)
MiR-20a-5p expression in breast cancer tissue was predictive for a greater benefit from bevacizumab-containing therapy in two independent cohorts.